A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths. In addition to hepatitis viral infections, several cohort studies have shown that diabetes mellitus is a risk factor of HCC, making the incidence alarming high. However, it has not been demonstrated directly how diabetes develops to HCC, because of its difficulty to follow changes of liver histology in diabetic populations. Here, we report that non-alcoholic steatohepatitis (NASH) is pivotal to link diabetes with HCC by establishing a novel, reproducible NASH-HCC model in mice. Neonatal male mice exposed to low-dose streptozotocin (STZ) developed liver steatosis with diabetes 1 week after feeding high-fat diet (HFD). Continuous HFD decreased hepatic fat deposit whilst increased lobular inflammation with foam cell-like macrophages, showing NASH pathology. In parallel with decreased phagocytosis of macrophages, fibroblasts accumulated to form "chicken-wired" fibrosis. All mice developed multiple HCC later. Female mice treated with STZ-HFD and male mice treated with STZ alone showed diabetes but never developed HCC by the absence of NASH-based fibrosis. Thus, the present study provides the evidence in novel mouse model that NASH-based fibrosis is an essential histological process for diabetic populations to accelerate the development of HCC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“To recapitulate this co-morbidity, a mouse model of diabetes due to beta cell depletion by a low dose of streptozotocin was subjected to subsequently high-fat diet feeding to induce MASH and hepatocellular carcinoma at 20 weeks (235, 236).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [235]
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Inflammation and insulin resistance
Shoelson, S. E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29069 · Cited by 4,769 · cited 1×
“First chemical intervention induced mild inflammation, a key pathogenesis of diabetes and metabolic disorders [31].”
BackgroundGender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production
Naugler, W. E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A. M., & Karin, M. (2007) · Science · doi:10.1126/science.1140485 · Cited by 1,955
Nonalcoholic fatty liver disease
Adams, L. A. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.045232 · Cited by 1,610
Insulin and insulin resistance:
Sowers, J. R., & Frohlich, E. D. (2004) · Medical Clinics of North America · doi:10.1016/s0025-7125(03)00128-7 · Cited by 1,518
Bugianesi, E., Leone, N., Vanni, E., Marchesini, G., Brunello, F., Carucci, P., Musso, A., De Paolis, P., Capussotti, L., Salizzoni, M., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.34168 · Cited by 1,439 · cited 3×
“Since NASH is a clinicopathologic syndrome encompassing a wide range of fatty liver diseases [22, 23], animal models that replicate the histopathology of human NASH are needed to investigate the mechanisms, biomarkers and treatments [14, 15].”
BackgroundNonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma: A Weighty Connection
Starley, B. Q., Calcagno, C. J., & Harrison, S. A. (2010) · Hepatology · doi:10.1002/hep.23594 · Cited by 1,336 · cited 1×
“Recently, non-alcoholic fatty liver disease (NAFLD) and its progressive form, non-alcoholic steatohepatitis (NASH), is revealed as an evolving major cause of virus-independent HCC, and NASH may account for a large proportion of HCC in developing countries [6].”
BackgroundAscha, M. S., Hanouneh, I. A., Lopez, R., Tamimi, T. A.-R., Feldstein, A. F., & Zein, N. N. (2010) · Hepatology · doi:10.1002/hep.23527 · Cited by 1,296 · cited 3×
“On the other hand, NASH is now revealed as a critical risk factor for HCC [3].”
BackgroundPostic, C., & Girard, J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34275 · Cited by 1,204 · cited 1×
“Persistent dietary intervention augments fat deposition in the liver with increased lipogenesis and fatty acid oxidation, leading to hepatocellular injury [33, 34].”
BackgroundGlypican-3: a novel serum and histochemical marker for hepatocellular carcinoma
Capurro, M., Wanless, I. R., Sherman, M., Deboer, G., Shi, W., Miyoshi, E., & Filmus, J. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00689-9 · Cited by 917 · cited 1×
“Glypican-3, a marker for HCC [26], was highly up-regulated only at HCC phase.”
BackgroundType 2 Diabetes-a Matter of ß-Cell Life and Death?
Rhodes, C. J. (2005) · Science · doi:10.1126/science.1104345 · Cited by 896 · cited 1×
“Since b-cell replication and neogenesis are actively detectable early after birth [32], low-dose STZ at this timing drives both islet injury and regenerative responses, leading to diabetic conditions.”
BackgroundModels of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ
Iredale, J. P. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30542 · Cited by 866 · cited 1×
“Collagen Type 1 and 3 were up-regulated prior to fibrosis, and this pattern was similar to other liver fibrosis models [13, 25].”
ResultMouse models in non‐alcoholic fatty liver disease and steatohepatitis research
Anstee, Q. M., & Goldin, R. D. (2006) · International Journal of Experimental Pathology · doi:10.1111/j.0959-9673.2006.00465.x · Cited by 714 · cited 2×
“Current animal models for NASH are generally divided into four categories; genetically engineered models, genetic leptin-mutation models, dietary methionine choline deficient (MCD) models and long-term high fat diet (HFD) models [12–16].”
BackgroundHepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas
Horie, Y., Suzuki, A., Kataoka, E., Sasaki, T., Hamada, K., Sasaki, J., Mizuno, K., Hasegawa, G., Kishimoto, H., Iizuka, M., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420513 · Cited by 698 · cited 1×
“Current animal models for NASH are generally divided into four categories; genetically engineered models, genetic leptin-mutation models, dietary methionine choline deficient (MCD) models and long-term high fat diet (HFD) models [12–16].”
BackgroundThe changing pattern of epidemiology in hepatocellular carcinoma
Nordenstedt, H., White, D. L., & El-Serag, H. B. (2010) · Digestive and Liver Disease · doi:10.1016/s1590-8658(10)60507-5 · Cited by 535 · cited 2×
“Although diabetes has been known as a risk factor for HCC [4, 5], the causal association between diabetes and HCC has not been directly demonstrated largely due to the difficulty in following changes in liver histological features.”
BackgroundMatsuzawa-Nagata, N., Takamura, T., Ando, H., Nakamura, S., Kurita, S., Misu, H., Ota, T., Yokoyama, M., Honda, M., Miyamoto, K.-I., et al. (2008) · Metabolism · doi:10.1016/j.metabol.2008.03.010 · Cited by 535
Ertle, J., Dechêne, A., Sowa, J., Penndorf, V., Herzer, K., Kaiser, G., Schlaak, J. F., Gerken, G., Syn, W., & Canbay, A. (2011) · International Journal of Cancer · doi:10.1002/ijc.25797 · Cited by 518
Tieu, B. C., Lee, C., Sun, H., LeJeune, W., Recinos, A., Ju, X., Spratt, H., Guo, D.-C., Milewicz, D., Tilton, R. G., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38308 · Cited by 461
Current views on type 2 diabetes
Lin, Y., & Sun, Z. (2010) · Journal of Endocrinology · doi:10.1677/joe-09-0260 · Cited by 457 · cited 1×
“Animal models for type 2 diabetes are also well investigated but there is no evidence that these models develop HCC [10, 11].”
BackgroundNew targets of β-catenin signaling in the liver are involved in the glutamine metabolism
Cadoret, A., Ovejero, C., Terris, B., Souil, E., Lévy, L., Lamers, W. H., Kitajewski, J., Kahn, A., & Perret, C. (2002) · Oncogene · doi:10.1038/sj.onc.1206118 · Cited by 410
Animal models of NASH: Getting both pathology and metabolic context right
Larter, C. Z., & Yeh, M. M. (2008) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2008.05543.x · Cited by 337 · cited 2×
“Current animal models for NASH are generally divided into four categories; genetically engineered models, genetic leptin-mutation models, dietary methionine choline deficient (MCD) models and long-term high fat diet (HFD) models [12–16].”
BackgroundShariff, M. I., Cox, I. J., Gomaa, A. I., Khan, S. A., Gedroyc, W., & Taylor-Robinson, S. D. (2009) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.09.35 · Cited by 333 · cited 1×
“Hepatocellular carcinoma (HCC) is the fifth most common form of cancer and the third common cause of cancerrelated deaths [1].”
BackgroundSahai, A., Malladi, P., Pan, X., Paul, R., Melin-Aldana, H., Green, R. M., & Whitington, P. F. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00199.2004 · Cited by 290 · cited 2×
“Current animal models for NASH are generally divided into four categories; genetically engineered models, genetic leptin-mutation models, dietary methionine choline deficient (MCD) models and long-term high fat diet (HFD) models [12–16].”
BackgroundResultMorphology of Alcoholic Liver Disease
Lefkowitch, J. H. (2005) · Clinics in Liver Disease · doi:10.1016/j.cld.2004.11.001 · Cited by 212 · cited 1×
“NASH [23, 24].”
Macrophage heterogeneity and tissue lipids
Gordon, S. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30992 · Cited by 207 · cited 1×
“Phagocytosis of macrophages decreased later as seen in human NASH [21], indicating altered function of macrophages at later phase of inflammation [36].”
BackgroundYoneyama, H., Matsuno, K., Zhang, Y., Murai, M., Itakura, M., Ishikawa, S., Hasegawa, G., Naito, M., Asakura, H., & Matsushima, K. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.1.35 · Cited by 199 · cited 3×
“Liver specimens were embedded and cryosectioned for immunohistochemistry of F4/80 [18].”
MethodSelf-citationRapid regression of atherosclerosis: insights from the clinical and experimental literature
Williams, K. J., Feig, J. E., & Fisher, E. A. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1086 · Cited by 189 · cited 1×
“These cellular events are similar to those of atherosclerosis [37].”
BackgroundNon-viral causes of hepatocellular carcinoma
Blonski, W. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i29.3603 · Cited by 174 · cited 2×
“Although diabetes has been known as a risk factor for HCC [4, 5], the causal association between diabetes and HCC has not been directly demonstrated largely due to the difficulty in following changes in liver histological features.”
BackgroundRecent advances in the natural history of hepatocellular carcinoma
Trevisani, F., Cantarini, M. C., Wands, J. R., & Bernardi, M. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn113 · Cited by 161
Diet-induced hepatocellular carcinoma in genetically predisposed mice
Hill-Baskin, A. E., Markiewski, M. M., Buchner, D. A., Shao, H., DeSantis, D., Hsiao, G., Subramaniam, S., Berger, N. A., Croniger, C., Lambris, J. D., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp236 · Cited by 146 · cited 2×
“Current animal models for NASH are generally divided into four categories; genetically engineered models, genetic leptin-mutation models, dietary methionine choline deficient (MCD) models and long-term high fat diet (HFD) models [12–16].”
BackgroundIkura, Y., Ohsawa, M., Suekane, T., Fukushima, H., Itabe, H., Jomura, H., Nishiguchi, S., Inoue, T., Naruko, T., Ehara, S., et al. (2006) · Hepatology · doi:10.1002/hep.21070 · Cited by 140 · cited 1×
“Persistent dietary intervention augments fat deposition in the liver with increased lipogenesis and fatty acid oxidation, leading to hepatocellular injury [33, 34].”
BackgroundPivotal role of TARC, a CC chemokine, in bacteria-induced fulminant hepatic failure in mice.
Yoneyama, H., Harada, A., Imai, T., Baba, M., Yoshie, O., Zhang, Y., Higashi, H., Murai, M., Asakura, H., & Matsushima, K. (1998) · Journal of Clinical Investigation · doi:10.1172/jci4619 · Cited by 139 · cited 3×
“To detect proliferative hepatocyte, immunostaining for BrdU was conducted on liver sections from normal (n = 3) or NASH–HCC model mice (n = 3–4) at 10, 12, 14, 16 and 18 weeks of age into which 100 mg/kg BrdU was injected intravenously at 1 h before being killed [17, 18].”
MethodSelf-citationMouse models for Type 1 Diabetes
Belle, T. L. V., Taylor, P., & von Herrath, M. G. (2009) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2009.03.008 · Cited by 128
Tamoxifen-induced fatty liver in patients with breast cancer
Ogawa, Y., Murata, Y., Nishioka, A., Inomata, T., & Yōshida, S. (1998) · The Lancet · doi:10.1016/s0140-6736(05)78493-2 · Cited by 123
Fujii, H., Ikura, Y., Arimoto, J., Sugioka, K., Iezzoni, J. C., Park, S. H., Naruko, T., Itabe, H., Kawada, N., Caldwell, S. H., et al. (2009) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.2055 · Cited by 121 · cited 1×
“Recruitment of inflammatory macrophages occurs to create inflammatory foci and to phagocytose lipid droplets [35].”
BackgroundEvaluation and management of obesity-related nonalcoholic fatty liver disease
Nugent, C., & Younossi, Z. M. (2007) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0879 · Cited by 101 · cited 2×
“Since NASH is considered as a hepatic manifestation of metabolic syndrome and highly associated with diabetes [7], it is speculated that the association between diabetes and HCC is related to the progression of NASH [8].”
BackgroundAnalysis of intestinal fibrosis in chronic colitis in mice induced by dextran sulfate sodium
Suzuki, K., Sun, X., Nagata, M., Kawase, T., Yamaguchi, H., Sukumaran, V., Kawauchi, Y., Kawachi, H., Nishino, T., Watanabe, K., et al. (2011) · Pathology International · doi:10.1111/j.1440-1827.2011.02647.x · Cited by 88 · cited 1×
“Real-time quantitative polymerase chain reaction (PCR) was performed using Real-time PCR DICE (TaKaRa Bio) for MCP-1, Timp-1 and Glypican-3 and ABI 7700 sequence-detector system (Applied Biosystems, Foster City, CA, USA) for the other genes with a set of primers and probes as previously described [20].”
MethodSelf-citationMouse models in liver cancer research: A review of current literature
Leenders, M. W. H., Nijkamp, M. W., & Rinkes, I. H. M. B. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.6915 · Cited by 88 · cited 1×
“Animal models for liver tumor such as carcinogeninduced models, tumor cell-implantation models, genetically engineered models and viral hepatocarcinogenesis models are well investigated [9], but these models show neither high reproducibility nor diabetes-related HCC.”
BackgroundDal Bello, B., Rosa, L., Campanini, N., Tinelli, C., Torello Viera, F., D'Ambrosio, G., Rossi, S., & Silini, E. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1978 · Cited by 81
Tung, H., Wang, J., Tseng, P., Hung, C., Kee, K., Chen, C., Chang, K., Lee, C., Changchien, C., Chen, Y.-D., et al. (2010) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.711 · Cited by 55 · cited 1×
“In fact, recent large cohort study indicated that neither diabetes nor overweight alone was a risk factor for HCC [29, 30], supporting the notion of its difficulty.”
BackgroundDecreased phagocytic activity of Kupffer cells in a rat nonalcoholic steatohepatitis model
Tsujimoto, T., Kawaratani, H., Kitazawa, T., Hirai, T., Ohishi, H., Kitade, M., Yoshiji, H., Uemura, M., & Fukui, H. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.6036 · Cited by 39 · cited 2×
“Phagocytosis of macrophages decreased later as seen in human NASH [21], indicating altered function of macrophages at later phase of inflammation [36].”
BackgroundDavila, J. A. (2010) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.715 · Cited by 21 · cited 1×
“In fact, recent large cohort study indicated that neither diabetes nor overweight alone was a risk factor for HCC [29, 30], supporting the notion of its difficulty.”
BackgroundMouse models in liver cancer research: A review of current literature
Martijn, Wh, Leenders, Maarten, Nijkamp, Inne, Borel, & Rinkes (2008) · World Journal of Gastroenterology · Cited by 11
Nonalcoholic Fatty Liver Disease progresses to HCC in the absence of apparent Cirrhosis
Ertle, J., Dechêne, A., Sowa, J., Penndorf, V., Herzer, K., Kaiser, G. M., Schlaak, J., Gerken, G., & Canbay, A. E. (2011) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0030-1269537 · Cited by 10
Cited by
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Senolytic CAR T cells reverse senescence-associated pathologies
Amor, C., Feucht, J., Leibold, J., Ho, Y.-J., Zhu, C., Alonso-Curbelo, D., Mansilla-Soto, J., Boyer, J. A., Li, X., Giavridis, T., et al. (2020) · Nature · doi:10.1038/s41586-020-2403-9 · Cited by 1,098
Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease
Lebeaupin, C., Vallée, D., Hazari, Y., Hetz, C., Chevet, E., & Bailly-Maitre, B. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.06.008 · Cited by 944
Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity
Shalapour, S., Lin, X.-J., Bastian, I. N., Brain, J., Burt, A. D., Aksenov, A. A., Vrbanac, A. F., Li, W., Perkins, A., Matsutani, T., et al. (2017) · Nature · doi:10.1038/nature24302 · Cited by 589
Hybrid Periportal Hepatocytes Regenerate the Injured Liver without Giving Rise to Cancer
Font-Burgada, J., Shalapour, S., Ramaswamy, S., Hsueh, B., Rossell, D., Umemura, A., Taniguchi, K., Nakagawa, H., Valasek, M. A., Ye, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.026 · Cited by 486
“, 2014b), and the STAM model of diabetes-promoted HCC (Fujii et al., 2013), using the Sox9-Cre;R26R reporter system.”
Influential
Metadata
- Authors
- Fujii, M., Shibazaki, Y., Wakamatsu, K., Honda, Y., Kawauchi, Y., Suzuki, K., Arumugam, S., Watanabe, K., Ichida, T., Asakura, H., & Yoneyama, H.
- Affiliations
- Stelic (Japan) (JP)
- Niigata University (JP)
- Niigata University of Pharmacy and Medical and Life Sciences (JP)
- Juntendo University (JP)
- Corresponding author
- Yoneyama, Hiroyuki
- Venue
- Medical Molecular Morphology
- Published
- 2013-02-22
- Volume
- 46
- Issue
- 3
- Pages
- 141-152
- ISSN
- 0918-4287 (ISSN-L)
- 1860-1480
- 1860-1499
- OpenAlex
- W2026450587
- Cited by
- 355
- References
- 45
- Citations by year
- 2026: 17 · 2025: 19 · 2024: 46 · 2023: 39 · 2022: 32 · 2021: 29 · 2020: 40 · 2019: 30 · 2018: 33 · 2017: 26 · 2016: 20 · 2015: 10 · 2014: 9 · 2013: 4
- FWCI
- 10.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- Locations
- Medical Molecular Morphology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (25860525, 23602012, 24590938)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Keywords
- nonalcoholic steatohepatitis, hepatocellular carcinoma, diabetes mellitus, streptozotocin-induced diabetes, high-fat diet, liver fibrosis, hepatic steatosis, hepatic macrophages, liver inflammation, sex differences, mouse model, cancer risk factors
- MeSH terms
- Animals, Diabetes Mellitus, Experimental, Disease Models, Animal, Fatty Liver, Female, Foam Cells, Carcinoma, Hepatocellular, Liver, Liver Neoplasms, Experimental, Male, Mice, Inbred C57BL, Mice, Diet, High-Fat, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.